Acceleron Pharma Inc. (NASDAQ:XLRN) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Acceleron Pharma to post earnings of ($0.63) per share for the quarter.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.69 million. During the same period in the prior year, the business posted ($0.59) earnings per share. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. On average, analysts expect Acceleron Pharma to post $-2.71 EPS for the current fiscal year and $-2.5 EPS for the next fiscal year.

Shares of Acceleron Pharma Inc. (XLRN) opened at 36.85 on Wednesday. The stock’s market capitalization is $1.43 billion. The stock has a 50 day moving average of $37.82 and a 200 day moving average of $32.82. Acceleron Pharma Inc. has a 52-week low of $23.07 and a 52-week high of $41.69.

TRADEMARK VIOLATION NOTICE: “Acceleron Pharma Inc. (XLRN) Scheduled to Post Earnings on Wednesday” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/25/acceleron-pharma-inc-xlrn-scheduled-to-post-earnings-on-wednesday.html.

A number of research firms have recently commented on XLRN. BidaskClub upgraded shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 6th. Zacks Investment Research upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Thursday, July 13th. Credit Suisse Group set a $35.00 target price on shares of Acceleron Pharma and gave the stock a “buy” rating in a report on Saturday, August 5th. Piper Jaffray Companies reiterated a “buy” rating and set a $40.00 target price on shares of Acceleron Pharma in a report on Friday, July 28th. Finally, Citigroup Inc. increased their target price on shares of Acceleron Pharma to $44.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $43.65.

In other news, SVP John D. Quisel sold 5,113 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the sale, the senior vice president now owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Corp /De/ Celgene acquired 745,592 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were purchased at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the purchase, the insider now directly owns 6,118,479 shares in the company, valued at $226,383,723. The disclosure for this purchase can be found here. Insiders have sold a total of 66,578 shares of company stock worth $2,518,117 in the last ninety days. Corporate insiders own 3.90% of the company’s stock.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Earnings History for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.